Tyrosine kinase inhibitors in cancer treatment (Part II)

Bibliography

• LEVITZKI A, GAZIT A: Tyrosine kinase inhibition: an ap- proach to drug development. Science (1995) 267:1782–1788.
   PubMed Web of Science ®Google Scholar
• FRY DW: Protein tyrosine kinases as therapeutic tar-gets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs 1994) 3:577–595.
   Google Scholar
• TRAXLER P, LYDON N: Recent advances in protein tyro-sine kinase inhibitors. Drugs Future (1995) 20:1261–1274.
   Google Scholar
• SPADA AP, MYERS MR: Small molecule inhibitors of ty-rosine kinase activity. Exp. Opin. Ther. Patents (1995) 5:805–817.
   Google Scholar
• BRIDGES AJ: The current status of tyrosine kinase in-hibitors: do the diarylamine inhibitors of the EGF re-ceptor represent a new beginning? Exp. Opin. Ther. Patents (1995) 5:1245–1257.
   Google Scholar
• TRAXLER P: Protein tyrosine kinase inhibitors in can-cer treatment. Exp. Opin. Ther. Patents (1997) 7:571–587.
   Web of Science ®Google Scholar
• STRAWN LM, SHAWVER LK: Tyrosine kinase in diseases. Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp. Opin. Invest. Drugs (1998) 7:533–573.
   Google Scholar
• BRIDGES AJ: Current progress towards the develop-ment of tyrosine kinase inhibitors as anticancer agents. Emerging Drugs: The Prospect for Improved Medi-cines. WC Bowman, JD Fitzgerald, JB Taylor (Eds.), Ashley Publications Ltd., London, UK (1998) 3:279–292.
   Google Scholar
• WARD WHJ, COOK PN, SLATER AM, DAVIES DH, HOLD-GATE GA, GREEN LR: Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. (1994) 48:659–666.
   Google Scholar
• FRY DW, KRAKER AJ, MCMICHAEL A et al.: A specific in-hibitor of the epidermal growth factor receptor tyro-sine kinase. Science (1994) 265:1093–1095.
   PubMed Web of Science ®Google Scholar
• REWCASTLE GW, DENNY WA, BRIDGES AJ et al.: Tyro-sine kinase inhibitors. 5. Synthesis and structure-activity realtionships for 4-[(phenylmethylaminol-and 4-(phenylamino)quinazolines as potent adeno-sine 5'-triphosphate binding site inhibitors of the tyro-sine kinase domain of the epidermal growth factor receptor. J. Merl. Chem. (1995) 38:3482–3487.
   Google Scholar
• THOMPSON AM, BRIDGES AJ, FRY DW, KRAKER AJ, DENNY WA: Tyrosine kinase inhibitors. 7. 7-Amino-4- (phenylamino)- and 7-Amino-4-Rphenyl-methyl)-aminopyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epi-dermal growth factor receptor. J. Merl. Chem. (1995) 3:3780–3788.
   Google Scholar
• REWCASTLE GW, PALMER BD, THOMPSON AM et al: Ty-rosine kinase inhibitors. 10. Isomeric 4-[(3-bromopheny1)-amino]-pyrido[d]pyrimidines are po-tent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. (1996) 39:1823–1835.
   Google Scholar
• REWCASTLE GW, BRIDGES AJ, FRY DW, RUBIN JA, DENNY WA: Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-) p he nylamino) pyrimido [5,4- di pyrimi di ne s de-signed as inhibitors of the epidermal growth factor re-ceptor. J. Med. Chem. (1997) 40:1820–1826.
   Google Scholar
• TRAXLER P, FURET P, METT H, BUCHDUNGER E, MEYERT, LYDON N: 4-(Phenylamino)pyrrolopyrimidines: po-tent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem (1996) 38:2285–2292.
   Google Scholar
• TRAXLER P, BOLD G, FREI J et al: Use of a Pharma-cophore model for the design of EGF-R tyrosine kinase inhibitors: 4- (phenylamino)pyrazolo dines. J. Merl. Chem (1997) 40:3601–3616.
   PubMed Web of Science ®Google Scholar
• FURET P, CARAVATTI G, LYDON N et al.: Modeling studyof protein kinase inhibitors: binding mode of staurosporine-origin of the selectivity of CGP 52 411. J. Comp.-Aid. Mol. Design (1995) 9:465–472.
   PubMed Web of Science ®Google Scholar
• ZHENG J, KNIGHTON DR, ZHENG J et al.: Crystal struc-ture of the catalytic subunit of cAMP-dependent pro-tein kinase complexed with MgATP and peptide inhibitor. Biochemistry (1993) 32:2154–2161.
   PubMed Web of Science ®Google Scholar
• SCHULZE-GAHMEN U, BRANDSEN J, JONES HD et al.: Mul-tiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopenteny-ladenine. Proteins (1995) 22:378–391.
   PubMed Web of Science ®Google Scholar
• MOHAMMADI M, MCMAHON G, SUN L et al.: Structure ofthe tyrosine kinase domain of fibroblast growt factor receptor in complex with inhibitors. Science (1997) 276:955–960.
   PubMed Web of Science ®Google Scholar
• PALMER BD, TRUMPP-KALLMEYER S, FRY DW; NELSONJM, SHOWALTER HDH, DENNY WA: Tyrosine kinase in-hibitors. 11. Soluble analogues of pyrrolo- and pyra-zoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and mod-eling of the mode of binding. J. Med. Chem. (1997) 40:1519–1529.
   Google Scholar
• TRUMPP-KALLMEYER S, RUBIN JR, HUMBLET C, HAMBYJM, SHOWALTER HDH: Development of a binding model to protein tyrosine kinases for substituted pyrido [2,3- d]pyrimidine inhibitors. J. Merl. Chem. (1998) 41:1752–1763.
   PubMed Web of Science ®Google Scholar
• BOS M, MENDELSOHN J, KIM YM, ALBANELL J, FRY DW,BASELGA J: PD 153 035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. (1997) 3:2099–2106.
   PubMed Web of Science ®Google Scholar
• KARNES WE, JR., WELLER SG, ADJEI PN et al.: Inhibitionof epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology (1998) 114:930–939.
   Google Scholar
• KUNKEL MW, HOOK KE, HOWARD CT et al.: Inhibition of the epidermal growth factor receptor tyrosine ki-nase by PD153035 in human A431 tumors in athymic nude mice. Invest. New Drugs (1996) 13:295–302.
   PubMed Web of Science ®Google Scholar
• NARLA RK, LIU X, MYERS DE, UCKUN FM: 4-(3'-Bromo-4'-hydroxyphenyl)amino-6,7-dimethoxy- quina-zoline: a novel quinazoline derivative with potent cy-totoxic activity against human glioblastoma cells. Clin. Cancer Res. (1998) 4:1405–1414.
   PubMed Web of Science ®Google Scholar
• WOODBURN JR, BARKER AJ, GIBSON KH et al: ZD 1839,an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Can-cer Res. (1997) 38:6333.
   Google Scholar
• KELLY AC, LAIGHT A, MORRIS CO, WOODBURN JR, RICH-MOND GHP: Phase I data of ZD 1839-an oral epidermal growth faxctor receptor tyrosine kinase inhibitor. 10th NCI-EORTC Symposium on New Drugs in Cancer Ther-apy. Amsterdam, The Netherlands (16–19 June, 1998) Poster.
   Google Scholar
• MOYER JD, BARBACCI EG, IWATA KK et al: Inducutionof Apopotosis and cell cycle arrest by CP-358 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57:4838–4848.
   PubMed Web of Science ®Google Scholar
• POTCHOIBA MJ, WEST M, SMOLAREK TA, POLLACK V,BAKER D: Tissue distribution of CP-358,774, a selective and potent EGF receptor tyrosine kinase inhibitor in 11lsI5 tumor-bearing athymic (nude) mice. Proc. Am. As-soc. Cancer Res. (1997) 38:3139.
   Google Scholar
• UPDIKE L, SMOLAREK, T, GUZZLE P P et al.: Pre-clinicalsafety assessment of CP-358, 774, an epidermal growth factor receptor tyrosine kinase inhibitor. Proc. Am. As-soc. Cancer Res. (1997) 38:3140.
   Google Scholar
• BAGULEY BC, MARSHALL ES, HOLDAWAY KM, REWCAS-TLE GW, DENNY WA: Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor fam-ily of tyrosine kinases. Eur. J. Cancer (1998) 34:1086–1090.
   PubMed Web of Science ®Google Scholar
• GIBSON KH, GRUNDY W, GODFREY AA et al.: Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumor activity of novel quinazolines. Bioorg. Med. Chem. Lett. (1997) 7:2723–2728.
   Web of Science ®Google Scholar
• DENNY WA: Quinazolines and pyridopyrimidine ac-rylamides: a new class of potent and selective irre-versible inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. 215th American Chemical Society National Meeting. Dallas, TX, USA (March 29-April 2, 1998). Lecture MEDI 118.
   Google Scholar
• NELSON JM, SLINTAK V, DENNY WA, SMAILL JB, REWCAS-TLE JB, SHOWALTER HDH: In vitro comparison of irre-versible vs. reversdible inhibition for a series of substituted quinazolines and pyridopyrimidines that are potent and specific inhibitors of the epidermal growth factor receptor (EGFR) family of tyrosine ki-nases. 89th Annual Meeting of theAmericanAssociation for Cancer Research. New Orleans, Louisiana, USA (March 28-April 1, 1998). Poster 2158.
   Google Scholar
• PATMORE SJ, ROBERTS BJ, STONER CL, VINCENT PW, LEOPOLD WR, DYKES DJ: In vivo evaluation of the irre-versible EGF receptor tyrosine kinase inhibitor PD 168393. 89th Annual Meeting of the American Association for Cancer Research. New Orleans, Louisiana, USA (March 28-April 1, 1998). Poster Discussion 3805.
   Google Scholar
• DENNY WA, SMAILL JB, PALMER BD, REWCASTLE GW,THOMPSON AM, SHOWALTER HDH: Structure-activity relationships for 4-anilinoquinazolines and related pyrido[d]pyrimidine acrylamides as specific, irre-versible inhibitors of the ATP site of the epidermal growth factor receptor. 89th Annual Meeting of the American Association for Cancer Research. New Orleans, Louisiana, USA (March 28-April 1, 1998). Poster Discussion 3804.
   Google Scholar
• FRY DW: Specific, irreversible inhibitors of the epider-mal growth factor receptor (EGFR) family of tyrosine kinases. Cell. Mol. Biol. Lett. (1998) 3:291.
   Google Scholar
• 4-Anilinoquinazoline derivatives. Exp. Opin. Ther. Pat-ents (1998) 8:475–478.
   Google Scholar
• FRY DW, NELSON JM, SLINTAK V et al.: Biochemical andantiproliferative properties of 4 -[Ar(alk)yl-amino]pyridopyrimidiens, a new chemical class of po-tent and specific epidermal growth factor receptor tyrosine kinase inhibitors. Biochem. Pharmacol. (1997) 54:877–887.
   PubMed Web of Science ®Google Scholar
• REWCASTLE GW, MURRAY DK, ELLIOTT WL et al.: Tyro-sine kinase inhibitors. 14. Structure-activity relation-ships for methyl-amino-substituted derivatives of 4 -((3 -bromo-phenylamino)- 6 -(methyl-amino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem (1998) 41:742–751.
   Google Scholar
• THOMPSON AM, MURRAY DK, ELLIOTT WL et al.: Tyro-sine kinase inhibitors. 13 Structure-activity relation-ships for soluble 7-substituted-4-((3-bromophenly) amino)pyrido [4,3-d]pyrimidines designed as inhibi-tors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Merl. Chem. (1997) 40:1820–1826.
   Google Scholar
• CONOLLY CJC, HAMBY JM, SCHROEDER MC et al.: Dis-covery and structure-activity studies of a novel series of pyrido[2,3-4pyrimidine tyrosine kinase inhibitors. Bioorg. Merl. Chem. Lett. (1997) 7:2415–2420.
   Google Scholar
• HAMBY JM, CONOLLY CJ, SCHROEDER MC et al.: Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Merl. Chem. (1997) 40:2296–2303.
   PubMed Web of Science ®Google Scholar
• DAHRING TK, LU GH, HAMBY JM, BATLEY BL, KRAKERAJ, PANEK RL: Inhibition of growth factor-mediated ty-rosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase in-hibitor. J. Pharmacol. Exp. Ther. (1997) 281:1446–1456.
   PubMedGoogle Scholar
• KLUTCHO SR, HAMBY JM, BOSCHELLI DH, WU Z, KRAKER AJ et al.: 2-Substituted aminopy-rido[2,3-d]pyrimidin-7(811)-ones. Structure-activity re-altionships against selected tyrosine kinases and in vi-tro and in vivo anticancer activity. J. Med. Chem. (1998) 41:3276–3292.
   Google Scholar
• BATLEY BL, DOHERTY AM, HAMBY JM et al: Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. (1998) 62:143–150.
   PubMed Web of Science ®Google Scholar
• PANEK RL, LU GH, DAHRING TKet aL: In vitro biological characterization and angiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine ki-nase. J. Pharmacol. Exp. Ther. (1998) 286:569–577.
   PubMed Web of Science ®Google Scholar
• DRISCOLL D, STEINKAMPF R, HAMBY J, SCHROEDER M, KLUTCHKO S, CONOLLY C: Evaluation of tyrosine ki-nase inhibitors in in vitro models of angiogenesis. 89th Annual Meeting of the American Association for Cancer Re-search. New Orleans, Louisiana, USA (March 28-April 1, 1998). Poster Discussion 654.
   Google Scholar
• SHOWALTER HDH: Designing selectivity into the pyrido[2,3-4-pyrimidines, a novel and potent class of tyrosine kinase inhibitors. 1st International Conference on Inhibitors of Protein Kinases. Warsaw, Poland (Septem-ber 15–20, 1998). Lecture.
   Google Scholar
• MOHAMMADI M, FROUM S, HAMBY JM et al.: Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. (1998) 17:5896–5904.
   PubMed Web of Science ®Google Scholar
• DIMITROFF CJ, KLOHS W, SHARMA A et al.: Evaluation of the effects of PD-166285 and PD-173074 on in vitro and in vivo angiogenesis. 89th Annual Meeting of the Ameri-can Association for Cancer Research. New Orleans, Louisi-ana, USA (March 28-April 1, 1998). Poster Discussion 653.
   Google Scholar
• SHOWALTER HD, KRAKER AJ: Small molecule inhibitors of the platelet-derived growth factor receptor, the fi-broblast growth factor receptor, and SRC familiy tyro-sine kinases. Pharamcol. Ther. (1997) 76:55–71.
   PubMed Web of Science ®Google Scholar
• PANEK RL, LU GH, KLUTCHKO SR et al.: In vitro charac-terization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. (1998) 283:1433–1444.
   Google Scholar
• KRAKER AJ, MOORE CW, HARTL BG, PANOPOULOS AD, LU GH, NELSON JM: Effects of c-src selective pyrido[2,3-d]pyramidine tyrosine kinase inhibitors on the phosphorylation of p130cas, paxillin and STAT3 and on proliferation in human carcinoma cell lines. 89th Annual Meeting of the American Association for Cancer Research. New Orleans, Louisian, USA (March 28-April 1, 1998). Poster Discussion 3800.
   Google Scholar
• BOSCHELLI D, WU Z, KLUTCHKO SR, SHOWALTER HDH et al The synthesis and tyrosine kinase inhibitory ac-tivity of a series of 2-amino-8 H-pyrido[2.3-d] pyrimidines. Identification of potent, selective platelet derived growth factor receptor tyrosine kinase inhibi-tors. J. Med. Chem. (1998) (In Press)
   Google Scholar
• METT H, BUCHDUNGER E, COZENS R, STOVER D, LYDONN: CGP 59326, a potent protein tyrosine kinase inhibi-tor which selectively blocks growth of epidermal growth factor receptor expressing tumor cells. 89th Annual Meeting of the American Association for Cancer Re-search. New Orleans, Louisiana, USA (1998). Poster Discus-sion 3809.
   Google Scholar
• PERROTTE P, KIM YK, KNIGHTON B, RADINSKY R, KIL-LION JJ, DINNEY CPN: Oral administration of a new epi-dermal growth factor receptor protein tyrosine kinase inhibitor, CGP 59326, inhibits growth of human tran-sitional cell carcinoma (TCC) of the bladder. 89th An-nual Meeting of the American Association for Cancer Research. New Orleans, Louisiana, USA (1998). Poster 2153.
   Google Scholar
• TRAXLER P, BOLD G, BUCHDUNGER E, LANG M, METT H,FURET P: The use of a pharmacophore model for the design of potent and selective EGFR tyrosine kinase in-hibitors. 215th American Chemical Society National Meet-ing. Dallas, Texas, USA (March 29-April 2, 1998). Lecture MEDI 104.
   Google Scholar
• MISSBACH M, GREEN J, SUSA Met al: Substituted 5,7-diphenyl pyrrolo[2,3-4pyrimidines: potent and spe-cific inhibitors of the tyrosine kinase PP60 C SRC. 215th American Chemical Society National Meeting. Dallas, Texas, USA (March 29- April 2, 1998). Lecture MEDI 168.
   Google Scholar
• ZIMMERMANN J, BUCHDUNGER E, METT H, MEYER T, LY-DON N, TRAXLER P: Phenylamino-pyrimidine (PAP) -d-erivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Merl. Chem. Lett. (1996) 6:1221–1226.
   Web of Science ®Google Scholar
• ZIMMERMANN J, BUCHDUNGER E, METT H, MEYER TH, LYDON N: Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) -derivatives. Bioorg. Merl. Chem. Letters (1997) 7:187–192.
   Web of Science ®Google Scholar
• BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Selec-tive inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine ki-nase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA (1995) 92:2558–2562.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Merl. (1996) 2:561–566.
   PubMed Web of Science ®Google Scholar
• DEININGER MWN, GOLDMAN JM, LYDON N, MELO JV:The tyrosine kinase inhibitor CGP 57148B, selectively inhibits the growth of Bcr-Abl-positive relies. Blood (1997) 90:3691–3698.
   PubMedGoogle Scholar
• GAMBACORTI-PASSERINI C, LE COUTRE P, MOLOGNI Letal.: Inhibition of the Abl kinase activity blocks the pro-liferation of Bcr/Abl+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. (1997) 23:380–394.
   Google Scholar
• CARROLL M, OHNO-JONES S, TAMURA S et al.: CGP 57148B, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-AB1, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 90:4947–4952.
   PubMed Web of Science ®Google Scholar
• BERAN M, CAO X, ESTROV Z eta].: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibi-tor (CGP 57148). Clin. Cancer Res. (1998) 4:1661–1672.
   Google Scholar
• THOMAS AP, GLARVEY D, CULSHAW JD, WOODBURN J: EGF RTK inhibitor SAR - discovery of 4,6-bis-anilinopyrimidines. 9th RSC-SCI Med. Chem. Symp. Cam-bridge, UK (Sept. 7–10, 1997). Poster 17.
   Google Scholar
• SUN L, TRAN N, TANG F et al: Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel se-ries of tyrosine kinase inhibitors that exhibit selectiv-ity toward particular receptor tyrosine kinases. J. Med. Chem. (1998) 41:2588–2603.
   PubMed Web of Science ®Google Scholar
• FONG TAT, SHAWER LK, APP H, SUN L, TANG C, RICE A:SU 5416: a potent and selective Flk-1/KDR kinase in-hibitor that blocks Flk-1 phosphorylation, endothelial cell mitogenesis, and tumor growth. 89th Annual Meet-ing of the American Association for Cancer Research. New Orleans, Louisiana, USA (March 28-April 1, 1998). Poster Discussion 3811.
   Google Scholar
• VAJKOCZY P, MENGER MD, VOLLMAR B, SCHILLING L,SCHMIEDEK P, ULLRICH A: Effect of the Flk-1 antagonist SU 5416 on tumor growth, angiogenesis and microhe-modynamics. 89th Annual Meeting of the American Asso-ciation for Cancer Research. New Orleans, Louisiana, USA (March 28-April 1, 1998). Poster Discussion 651.
   Google Scholar
• ROSEN LS, KABBINAVAR F, ROSEN P, MULAY M, QUIGLEYS, HANNAH AL: Phase I trials of SU 5416, a novel angio-genesis inhibitor, in patients with advanced malignan-cies. 10th NCEEORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, The Netherlands (16–19 June, 1998). Poster 290.
   Google Scholar
• SHAWVER LK, SCHWARTZ DP, MANN E et al.: Inhibitionof platelet-derived growth factor-mediated signal transduction and tumor growth by NR4-trifluoromethyl)-phenyllisoxazole-4-carboxamide. Clin. Cancer Res. (1997) 44:1167–1177.
   Google Scholar
• MASON W, MALKIN M, LIEBERMANN F, CROPP G, HAN-NAH A: Pharmacokinetics of SU 101, a novel signal transduction inhibitor, in patients with recurrent ma-lignant glioma. 87th Annaual Meeting of the American As-sociation for Cancer Research. Washington, DC, USA (20–24 April, 1996). Poster 1145.
   Google Scholar
• NIKCEVICH DA, FINNEGAN A, CHONG AS-F, WILLIAMSJW, BREMER EG: Inhibition of interleukin 3 (IL-2)-stim-ulated tyrosine kinase activity by leflunomide. Agents Actions (1994) 41:C279–C282.
   Google Scholar
• XU X, WILLIAMS JW, BREMER EG, FINNEGAN A, CHONGAS-F: Inhibition of protein tyrosine phosphorylation in T-cells by a novel immunosuppressive agent, leflu-nomide. J. Biol. Chem. (1995) 270:12398–12403.
   PubMed Web of Science ®Google Scholar
• XU X, WILLIAMS JW, GONG A, FINNEGAN A, CHONG AS-F: Two activities of the immunosuppressive me-tabolite of leflunomide, A77 1726; inhibition of py-rimidine nucleotide biosynthesis and protein tyrosine phosphorylation. Biochem. Pharmacol. (1996) 52:527–534.
   PubMed Web of Science ®Google Scholar
• MATTAR T, KOCHHAR K, BARTLETT R, BREMER EG, FIN-NEGAN A: Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. (1993) 334:161–164.
   PubMed Web of Science ®Google Scholar
• ELDER RT, XU X, WILLIAMS JW, GONG H, FINNEGAN A,CHONG AS-F: The immunisuppressive metabolite of le-flunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. (1997) 159:22–27.
   PubMed Web of Science ®Google Scholar
• CHERWINSKI HM, BYARS N, BALLARON SJ, NAKANO GM,YOUNG JM, RANSON JT: Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm. Res. (1995) 44:317–322.
   PubMed Web of Science ®Google Scholar
• GEORGE DJ, DIONNE CA, JANI L, LAMB J, ISAACS JT: Com-bined effects of the Trk tyrosine kinase inhibitor, CEP-751 (KT-6587), and castration of Dunnung H rat pros-tate cancers in vivo. 89th Annual Meeting of the American Association for Cancer Research. New Orleans, Louisiana, USA (March 28-April 1, 1998). Lecture 4387.
   Google Scholar
• HUDKINS RL, IQBAL M, PARK C-H et al: Prodrug esters of the indolocarbazole CEP-751 (KT-6587). Bioorg. Med. Chem. Lett. (1998) 8:1873–1876.
   PubMedGoogle Scholar
• SPACEY GD, UINGS IJ, SLATER M, HIRST S, BONSER RW: Indolocarbazoles. Potent and selective inhibitors of platelet-derived growth factor receptor autophospho-rylation. Biochem. Pharmacol (1998) 55:261–171.
   Google Scholar
• WOOD J, BUCHDUNGER E, COZENS R et al.: Pharma-cological profile of a potent and orally active inhibitor of VEGF receptor tyrosine kinases. 89th Annual Meeting of the American Association for Cancer Research. New Or-leans, Louisiana, USA (March 28-April 1, 1998). Abstract 655.
   Google Scholar
• TRAXLER P, GREEN J, METT H, SEQUIN U, FURET P: Use of a pharmacophore model for the design of EGFR tyro-sine kinase inhibitors: isoflavones and 3-pheny1-4 (1H)-quinolones. J. Med. Chem. (1998). (Submit-ted).
   Google Scholar
• PALUMBO GA, YAROM N, GAZIT A et al: The tyrphostin AG17 induces apopotosis and inhibition of CDK2 ac-tivity in a lymphoma cell line that overexpresses bc1-2. Cancer Res. (1997) 57:2434–2439.
   PubMedGoogle Scholar
• MEYDAN N, GRUNBERGER T, DADI H et al.: Inhibition ofacute lymphoblastic leukemia by a JAK-2 inhibitor. Na-ture (1996) 379:645–648.
   PubMed Web of Science ®Google Scholar
• BEN-BASSAT H, ROSENBAUM-MITRANI S, HARTZSTARK Zet al.: Inhibitors of epidermal growth factor reeptor ki-nase and cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of hu-man papilloma virus 16-immortalized human kera-tinocytes. Cancer Res. (1997) 57:3741–3750.
   Google Scholar
• KLEINBERGER-DORON N, SHELAH N, CAPONE R, GAZITA, LEVITZKI A: Inhibition of CDK2 activation by se-lected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp. Cell. Res. (1998) 241:340–351.
   PubMed Web of Science ®Google Scholar
• BANAI S, WOLF Y, GOLOMB G et al: PDGF- receptor ty- rosine kinase blocker AG 1295 selectively attenuates smooth muscle cell growth in vitro and reduces neoin-timal formation after balloon angioblasty in swine. Circulation (1998) 97: 1960-1969.
   Google Scholar